Prognostic impact of Des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma

N. Harimoto, Y. Yoshida, T. Kurihara, K. Takeishi, S. Itoh, N. Harada, E. Tsujita, Y. I. Yamashita, H. Uchiyama, Y. Soejima, T. Ikegami, T. Yoshizumi, H. Kawanaka, T. Ikeda, K. Shirabe, H. Saeki, E. Oki, Y. Kimura, Y. Maehara

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Although the Milan criteria are widely accepted for liver transplantation (LT) in patients for hepatocellular carcinoma (HCC), they have not been fully evaluated for salvage LT in patients with recurrent HCC. We have previously reported outcomes of living-donor LT (LDLT) for HCC and identified 2 risk factors affecting recurrence-free survival (RFS): tumor size >5 cm and des-γ-carboxyl prothrombin (DCP) concentration >300 mAU/mL (Kyushu University criteria). This study was designed to clarify risk factors for tumor recurrence after LDLT in patients with recurrent HCC. Methods Outcomes in 114 patients who underwent LDLT for recurrent HCC were analyzed retrospectively. RFS rates after LDLT were calculated, and risk factors for tumor recurrence were identified. Results The 1-, 3-, and 5-year RFS rates after LDLT were 90.6%, 80.4%, and 78.8%, respectively. Univariate analysis showed that tumor recurrence was associated with alpha-fetoprotein concentration ≥300 ng/mL, DCP concentration ≥300 mAU/mL, tumor number ≥4, tumor size ≥5 cm, transarterial chemotherapy before LDLT, duration of last treatment of HCC to LDLT <3 months, bilobar distribution, exceeding Milan criteria, exceeding Kyushu University criteria, poor differentiation, and histologic vascular invasion. Multivariate analysis showed that DCP ≥300 mAU/mL (P =.03) and duration from last treatment to LDLT <3 months (P =.01) were independent predictors of RFS. Conclusions DCP concentration and time between last treatment and LDLT are prognostic of RFS in patients undergoing LDLT for HCC.

Original languageEnglish
Pages (from-to)703-704
Number of pages2
JournalTransplantation Proceedings
Volume47
Issue number3
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Living Donors
Prothrombin
Liver Transplantation
Hepatocellular Carcinoma
Recurrence
Neoplasms
Survival
Survival Rate
Prothrombin Time
alpha-Fetoproteins
Blood Vessels
Therapeutics
Multivariate Analysis
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Prognostic impact of Des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma. / Harimoto, N.; Yoshida, Y.; Kurihara, T.; Takeishi, K.; Itoh, S.; Harada, N.; Tsujita, E.; Yamashita, Y. I.; Uchiyama, H.; Soejima, Y.; Ikegami, T.; Yoshizumi, T.; Kawanaka, H.; Ikeda, T.; Shirabe, K.; Saeki, H.; Oki, E.; Kimura, Y.; Maehara, Y.

In: Transplantation Proceedings, Vol. 47, No. 3, 01.04.2015, p. 703-704.

Research output: Contribution to journalArticle

Harimoto, N, Yoshida, Y, Kurihara, T, Takeishi, K, Itoh, S, Harada, N, Tsujita, E, Yamashita, YI, Uchiyama, H, Soejima, Y, Ikegami, T, Yoshizumi, T, Kawanaka, H, Ikeda, T, Shirabe, K, Saeki, H, Oki, E, Kimura, Y & Maehara, Y 2015, 'Prognostic impact of Des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma', Transplantation Proceedings, vol. 47, no. 3, pp. 703-704. https://doi.org/10.1016/j.transproceed.2014.09.178
Harimoto, N. ; Yoshida, Y. ; Kurihara, T. ; Takeishi, K. ; Itoh, S. ; Harada, N. ; Tsujita, E. ; Yamashita, Y. I. ; Uchiyama, H. ; Soejima, Y. ; Ikegami, T. ; Yoshizumi, T. ; Kawanaka, H. ; Ikeda, T. ; Shirabe, K. ; Saeki, H. ; Oki, E. ; Kimura, Y. ; Maehara, Y. / Prognostic impact of Des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma. In: Transplantation Proceedings. 2015 ; Vol. 47, No. 3. pp. 703-704.
@article{412bae7385fe4295888f189b99dc5bd1,
title = "Prognostic impact of Des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma",
abstract = "Background Although the Milan criteria are widely accepted for liver transplantation (LT) in patients for hepatocellular carcinoma (HCC), they have not been fully evaluated for salvage LT in patients with recurrent HCC. We have previously reported outcomes of living-donor LT (LDLT) for HCC and identified 2 risk factors affecting recurrence-free survival (RFS): tumor size >5 cm and des-γ-carboxyl prothrombin (DCP) concentration >300 mAU/mL (Kyushu University criteria). This study was designed to clarify risk factors for tumor recurrence after LDLT in patients with recurrent HCC. Methods Outcomes in 114 patients who underwent LDLT for recurrent HCC were analyzed retrospectively. RFS rates after LDLT were calculated, and risk factors for tumor recurrence were identified. Results The 1-, 3-, and 5-year RFS rates after LDLT were 90.6{\%}, 80.4{\%}, and 78.8{\%}, respectively. Univariate analysis showed that tumor recurrence was associated with alpha-fetoprotein concentration ≥300 ng/mL, DCP concentration ≥300 mAU/mL, tumor number ≥4, tumor size ≥5 cm, transarterial chemotherapy before LDLT, duration of last treatment of HCC to LDLT <3 months, bilobar distribution, exceeding Milan criteria, exceeding Kyushu University criteria, poor differentiation, and histologic vascular invasion. Multivariate analysis showed that DCP ≥300 mAU/mL (P =.03) and duration from last treatment to LDLT <3 months (P =.01) were independent predictors of RFS. Conclusions DCP concentration and time between last treatment and LDLT are prognostic of RFS in patients undergoing LDLT for HCC.",
author = "N. Harimoto and Y. Yoshida and T. Kurihara and K. Takeishi and S. Itoh and N. Harada and E. Tsujita and Yamashita, {Y. I.} and H. Uchiyama and Y. Soejima and T. Ikegami and T. Yoshizumi and H. Kawanaka and T. Ikeda and K. Shirabe and H. Saeki and E. Oki and Y. Kimura and Y. Maehara",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.transproceed.2014.09.178",
language = "English",
volume = "47",
pages = "703--704",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Prognostic impact of Des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma

AU - Harimoto, N.

AU - Yoshida, Y.

AU - Kurihara, T.

AU - Takeishi, K.

AU - Itoh, S.

AU - Harada, N.

AU - Tsujita, E.

AU - Yamashita, Y. I.

AU - Uchiyama, H.

AU - Soejima, Y.

AU - Ikegami, T.

AU - Yoshizumi, T.

AU - Kawanaka, H.

AU - Ikeda, T.

AU - Shirabe, K.

AU - Saeki, H.

AU - Oki, E.

AU - Kimura, Y.

AU - Maehara, Y.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background Although the Milan criteria are widely accepted for liver transplantation (LT) in patients for hepatocellular carcinoma (HCC), they have not been fully evaluated for salvage LT in patients with recurrent HCC. We have previously reported outcomes of living-donor LT (LDLT) for HCC and identified 2 risk factors affecting recurrence-free survival (RFS): tumor size >5 cm and des-γ-carboxyl prothrombin (DCP) concentration >300 mAU/mL (Kyushu University criteria). This study was designed to clarify risk factors for tumor recurrence after LDLT in patients with recurrent HCC. Methods Outcomes in 114 patients who underwent LDLT for recurrent HCC were analyzed retrospectively. RFS rates after LDLT were calculated, and risk factors for tumor recurrence were identified. Results The 1-, 3-, and 5-year RFS rates after LDLT were 90.6%, 80.4%, and 78.8%, respectively. Univariate analysis showed that tumor recurrence was associated with alpha-fetoprotein concentration ≥300 ng/mL, DCP concentration ≥300 mAU/mL, tumor number ≥4, tumor size ≥5 cm, transarterial chemotherapy before LDLT, duration of last treatment of HCC to LDLT <3 months, bilobar distribution, exceeding Milan criteria, exceeding Kyushu University criteria, poor differentiation, and histologic vascular invasion. Multivariate analysis showed that DCP ≥300 mAU/mL (P =.03) and duration from last treatment to LDLT <3 months (P =.01) were independent predictors of RFS. Conclusions DCP concentration and time between last treatment and LDLT are prognostic of RFS in patients undergoing LDLT for HCC.

AB - Background Although the Milan criteria are widely accepted for liver transplantation (LT) in patients for hepatocellular carcinoma (HCC), they have not been fully evaluated for salvage LT in patients with recurrent HCC. We have previously reported outcomes of living-donor LT (LDLT) for HCC and identified 2 risk factors affecting recurrence-free survival (RFS): tumor size >5 cm and des-γ-carboxyl prothrombin (DCP) concentration >300 mAU/mL (Kyushu University criteria). This study was designed to clarify risk factors for tumor recurrence after LDLT in patients with recurrent HCC. Methods Outcomes in 114 patients who underwent LDLT for recurrent HCC were analyzed retrospectively. RFS rates after LDLT were calculated, and risk factors for tumor recurrence were identified. Results The 1-, 3-, and 5-year RFS rates after LDLT were 90.6%, 80.4%, and 78.8%, respectively. Univariate analysis showed that tumor recurrence was associated with alpha-fetoprotein concentration ≥300 ng/mL, DCP concentration ≥300 mAU/mL, tumor number ≥4, tumor size ≥5 cm, transarterial chemotherapy before LDLT, duration of last treatment of HCC to LDLT <3 months, bilobar distribution, exceeding Milan criteria, exceeding Kyushu University criteria, poor differentiation, and histologic vascular invasion. Multivariate analysis showed that DCP ≥300 mAU/mL (P =.03) and duration from last treatment to LDLT <3 months (P =.01) were independent predictors of RFS. Conclusions DCP concentration and time between last treatment and LDLT are prognostic of RFS in patients undergoing LDLT for HCC.

UR - http://www.scopus.com/inward/record.url?scp=84928371186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928371186&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2014.09.178

DO - 10.1016/j.transproceed.2014.09.178

M3 - Article

C2 - 25819732

AN - SCOPUS:84928371186

VL - 47

SP - 703

EP - 704

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -